A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) IN COMBINATION WITH CARBOPLATIN PLUS PEMETREXED VERSUS PLATINUM PLUS PEMETREXED OR NIVOLUMAB PLUS IPILIMUMAB IN PARTICIPANTS WITH UNRESECTABLE PLEURAL MESOTHELIOMA (EVOLVE-MESO)

Registry ID

D7988C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2025-06-12

Last update

2023-08-17

Conditions

• PLEURAL MESOTHELIOMA

Related clinical trials

• A PHASE II RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA

View on source registry